Article

CASPAR Criteria for Psoriatic Arthritis Adapt Well for Retrospective Use

The sensitivity, specificity, and feasibility of the ClASsification criteria for Psoriatic ARthritis (CASPAR) are maintained when they are adapted for retrospective use to classify an established research cohort from medical records.

The sensitivity, specificity, and feasibility of the ClASsification criteria for Psoriatic ARthritis (CASPAR) are maintained when they are adapted for retrospective use to classify an established research cohort from medical records. The sensitivity and specificity are similar to those in previous reports even when data points are missing.

Tillett and colleagues applied the CASPAR criteria to the records of 480 patients with psoriatic arthritis (PsA) and 100 consecutive controls who had inflammatory arthritis. The CASPAR criteria consist of confirmed inflammatory articular disease with at least 3 points from current psoriasis, a history or family history of psoriasis, dactylitis, rheumatoid factor (RF) negativity, and other factors. The CASPAR score was modified for retrospective use; "inflammation" and “current psoriasis” were scored if they had ever been confirmed in the clinic. An expert in PsA provided clinical diagnosis.

Of 456 physician diagnoses of PsA, 8 did not fulfill the CASPAR criteria. Only 1 had all the CASPAR data available. Another 7 had no radiographs or no RF tests performed to allow for complete assessment. Sensitivity was 99.7%, and specificity was 99.1%. There was excellent interrater reliability.

The authors noted that the criteria were found to be easy and practical to apply to case records.

Related Videos
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
© 2024 MJH Life Sciences

All rights reserved.